Novartis Acquires IFM Tre for $1.575 Billion to Advance NLRP3 Antagonist Portfolio Targeting Intracellular Innate Immune Signaling

VCBeat (WeChat Official Account: vcbeat) has learned that biopharmaceutical company IFM Therapeutics (IFM) announced on April 1 that Novartis had entered into a definitive agreement to acquire all outstanding equity interests in IFM’s subsidiary, IFM Tre. Upon closing of the transaction, IFM will receive an upfront payment of $310 million and will be eligible for contingent payments of up to $1.265 billion, bringing the total deal value to $1.575 billion.

Novartis, founded in Switzerland in 1996, is one of the world’s top three pharmaceutical companies, engaged in the global research, development, manufacturing, and sales of a broad portfolio of medicinal products. Its Innovative Medicines division provides patented prescription drugs aimed at improving health outcomes for patients and healthcare providers. This division is also responsible for commercializing products across therapeutic areas including oncology and rare diseases, ophthalmology, immunology, dermatology, neuroscience, respiratory diseases, cardiometabolic disorders, and established medicines. Through this acquisition, Novartis will obtain full rights to IFM Tre’s portfolio of NLRP3 antagonists.

IFM Therapeutics is a subsidiary of IFM Therapeutics, a private biopharmaceutical company focused on developing therapies that target novel regulators of the innate immune system. In July 2018, IFM Therapeutics prioritized the development of a portfolio of NLRP3 antagonists for the treatment of inflammatory diseases. This portfolio comprises one clinical-stage program and two preclinical programs. The clinical-stage program features IFM-2427, a first-in-class systemic NLRP3 antagonist in clinical development for chronic inflammatory conditions, primarily atherosclerosis and non-alcoholic steatohepatitis (NASH). The two preclinical programs include a gut-restricted molecule for the treatment of inflammatory bowel disease (IBD) and a central nervous system (CNS)-penetrant molecule, both in the preclinical stage.

NLRP3 is an intracellular innate immune signaling receptor that enables immune cells to detect the presence of pro-inflammatory exogenous or endogenous molecules. These molecules signal infection, tissue damage, or metabolic disorders. Such signals trigger the assembly of a multiprotein complex known as the inflammasome, thereby initiating an immune response. Although this response can be employed to defend against foreign pathogens, aberrant or chronic activation of the NLRP3 inflammasome is known to contribute to the onset and progression of numerous diseases. Inappropriate inflammatory responses mediated by the NLRP3 pathway in the innate immune system are considered fundamental to the pathogenesis of various severe diseases.

IFM Tre’s projects target the innate immune system exclusively by inhibiting NLRP3 pathway-mediated inflammatory responses, without suppressing other immune pathways, thereby allowing the body to freely mount inflammatory responses against harmful pathogens. The combination of NLRP3 antagonists offers a novel approach to preventing severe chronic inflammation. The company is developing chemically gut-targeted and CNS-penetrant candidate drugs to address a broad range of NLRP3-driven indications, including metabolic, fibrotic, autoimmune, autoinflammatory, and neurological diseases.

Jay Bradner, President of the Novartis Institutes for BioMedical Research, stated, “IFM Tre’s investigational compounds have been demonstrated to fine-tune the immune system, offering a potentially effective approach for treating various inflammation-related diseases. We will leverage our expertise in this field to advance the research, development, and manufacturing of these drugs.”

Regarding this acquisition, Dr. Gary D. Glick, Co-founder and CEO of IFM Therapeutics, stated, “This acquisition represents a significant milestone in the new generation of therapies for severe inflammation. We are delighted to partner with Novartis, which possesses deep expertise and the capability to bring treatments for inflammatory and autoimmune diseases to market.”

The transaction has been approved by IFM’s Board of Directors and shareholders and is expected to be completed in the second quarter of 2019.

(Compiled by Li Chengping)